15
Participants
Start Date
September 30, 2011
Primary Completion Date
February 28, 2014
Study Completion Date
February 28, 2014
Akt Inhibitor MK2206
Given PO
Bendamustine Hydrochloride
Given IV
Laboratory Biomarker Analysis
Correlative studies
Rituximab
Given IV
Grady Memorial Hospital, Delaware
Knox Community Hospital, Mount Vernon
Licking Memorial Hospital, Newark
Saint Ann's Hospital, Westerville
Fairfield Medical Center, Lancaster
Riverside Methodist Hospital, Columbus
Columbus CCOP, Columbus
Grant Medical Center, Columbus
Mount Carmel Health Center West, Columbus
Doctors Hospital, Columbus
Genesis HealthCare System, Zanesville
Springfield Regional Medical Center, Springfield
Adena Regional Medical Center, Chillicothe
Southern Ohio Medical Center, Portsmouth
Marietta Memorial Hospital, Marietta
Siouxland Regional Cancer Center, Sioux City
Mercy Medical Center-Sioux City, Sioux City
Saint Luke's Regional Medical Center, Sioux City
Lakeview Hospital, Stillwater
Regions Hospital, Saint Paul
United Hospital, Saint Paul
Minnesota Oncology Hematology PA-Maplewood, Maplewood
Saint John's Hospital - Healtheast, Maplewood
Minnesota Oncology and Hematology PA-Woodbury, Woodbury
Fairview Ridges Hospital, Burnsville
Hutchinson Area Health Care, Hutchinson
Saint Francis Regional Medical Center, Shakopee
Ridgeview Medical Center, Waconia
Abbott-Northwestern Hospital, Minneapolis
Hennepin County Medical Center, Minneapolis
Metro-Minnesota NCI Community Oncology Research Program, Saint Louis Park
Park Nicollet Clinic - Saint Louis Park, Saint Louis Park
North Memorial Medical Health Center, Robbinsdale
Unity Hospital, Fridley
Mercy Hospital, Coon Rapids
Fairview-Southdale Hospital, Edina
Essentia Health Cancer Center, Duluth
Essentia Health Saint Mary's Medical Center, Duluth
Miller-Dwan Hospital, Duluth
Mayo Clinic, Rochester
Rice Memorial Hospital, Willmar
Essentia Health Saint Joseph's Medical Center, Brainerd
Rapid City Regional Hospital, Rapid City
Mayo Clinic in Arizona, Scottsdale
National Cancer Institute (NCI)
NIH